FDA is seeking public input on the clinical utility and safety concerns associated with the higher range of opioid analgesic dosing (both in terms of higher strength products and higher daily doses) in the outpatient set...
Content in this section will include AAPM advocacy efforts, legislative news, public statements, etc.
Sagent Pharmaceuticals, announced the voluntary nationwide recall of Lot Number M813513 of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL). This product was manufactured by Zydus (Cadila Healthcare Limited) and distributed by Sagent Pharmaceuticals, Inc. Sagent has initiated this voluntary recall of Ketorolac Tromethamine Injection, USP to the to the user level due to microbial growth detected during a routine simulation of the manufacturing process, which represents the potential introduction of microorganisms into the products.
Earlier this year, a consensus panel report addressing the challenges of implementing the CDC Guideline for Prescribing Opioids for Chronic Pain was published in Pain Medicine . The report, authored by a multidisciplinar...
Alvogen, Inc. is voluntarily recalling two lots of Fentanyl Transdermal System 12 mcg/h transdermal patches to the consumer level. A small number of cartons labeled 12 mcg/h Fentanyl Transdermal System patches contained 50 mcg/h patches. The 50 mcg/h patches that were included in cartons labeled 12 mcg/h are individually labeled as 50 mcg/h.
As one of the organizations in the AMA Opioid Taskforce, AAPM is working with the American Medical Association (AMA) to gather information on barriers to treatment. AAPM and the AMA request 10-15 minutes of your time to ...
The American Society of Clinical Oncology, the American Society of Hematology, and the National Comprehensive Cancer Network® received a letter from the Centers for Disease Control and Prevention (CDC) clarifying the CDC Guideline for Prescribing Opioids for Chronic Pain on prescribing opioids to manage pain from certain conditions.
Comments from the American Academy of Pain Medicine The American Academy of Pain Medicine thanks the Agency for the opportunity to comment on The Evidence-based Practice Center Program at the Agency for Healthcare Resear...
The U.S. Food and Drug Administration (FDA) has received reports of serious harm in patients who are physically dependent on opioid pain medicines suddenly having these medicines discontinued or the dose rapidly decreased. These include serious withdrawal symptoms, uncontrolled pain, psychological distress, and suicide.
This funding will expand access to treatment that works, especially to medication-assisted treatment (MAT) with appropriate social supports.
The Agency for Healthcare Research and Quality (AHRQ) has posted key questions for the systematic review on Management of Primary Headaches in Pregnancy for comment through April 11, as well as a draft technical brief on...